Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05830500 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of May 2023 to Jun 19, 2023v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
Trial Details
NCT Number NCT05830500
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Medullary Thyroid Cancer
Enrollment 360 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov